Is NVO's Major Restructuring Plan an Indication to Sell the Stock?

Novo Nordisk (NVO) has initiated a significant restructuring plan, including 9,000 job cuts and DKK 8 billion in one-time charges, in response to slower-than-anticipated uptake of its key semaglutide drugs like Wegovy and intensifying competition from Eli Lilly. The overhaul, designed to streamline operations and reallocate resources, has prompted NVO to sharply reduce its 2025 operating profit growth outlook to 4-10% from a prior 10-16%, indicating near-term earnings pressure. Despite these immediate headwinds and a 'Strong Sell' rating, the company anticipates annualized savings of DKK 8 billion by 2026, aiming to reinvest in R&D and manufacturing to secure long-term competitiveness in the expanding diabetes and obesity markets.

Analysis

Novo Nordisk is undertaking a significant strategic overhaul, cutting 9,000 jobs, or 11% of its workforce, to generate DKK 8 billion in annualized savings by 2026. This restructuring is a direct response to a major guidance cut in July, driven by slower-than-expected sales momentum for its key GLP-1 drugs, Wegovy and Ozempic, and intensifying competition from Eli Lilly's tirzepatide products. The U.S. market has presented specific challenges, including lagging adoption and counterfeit sales. The immediate financial impact is substantial, with the company booking DKK 9 billion in one-time expenses in Q3 2025 and slashing its 2025 operating profit growth forecast to 4-10% from 10-16%. This has contributed to the stock's 36.9% year-to-date decline and downward revisions to 2025 and 2026 EPS estimates. Despite these near-term headwinds, Novo Nordisk retains fundamental strengths. Wegovy sales still grew 78% year-over-year in the first half of 2025, and the company is securing its position through label expansions into cardiovascular and liver disease, a preferred status with CVS Caremark, and real-world data suggesting cardiovascular superiority over tirzepatide. The company's valuation reflects the market's concern, with its forward P/E of 13.56 trading at a discount to the industry and its historical average. Future growth hinges on the successful execution of its restructuring, the defense of its market share against Lilly, and the progression of its pipeline, which includes key late-stage assets like oral semaglutide, CagriSema, and Amycretin.

Key Decisions for Investors

• Given the significant cut to the 2025 profit outlook, high restructuring costs, and negative stock momentum, a cautious short-term stance is warranted; investors should monitor for tangible signs of operational stabilization and market share defense against Eli Lilly before increasing exposure.
• For long-term investors, the current discounted valuation may present a future opportunity, but it is contingent on key pipeline catalysts, such as the FDA's year-end decision on oral semaglutide and progress updates on CagriSema and Amycretin.
• Closely track competitive dynamics by monitoring prescription data for both NVO and LLY drugs and pay-or formulary decisions, as NVO's ability to leverage differentiators like its proven cardiovascular benefits will be critical to its long-term success in the contested obesity market.